A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
The University of Michigan Comprehensive Cancer Center is multidisciplinary, which means treatment plans are developed with input from many experts who share their experiences and knowledge of specific cancer to provide the very best options.
Ann Arbor, Michigan Clinical Trial Location
University of Michigan Comprehensive Cancer Center
1500 E Medical Center Dr,
Ann Arbor, MI 48109